J. Goldman & CO LP Rocket Pharmaceuticals, Inc. Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
A detailed history of J. Goldman & CO LP transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 20,300 shares of RCKT stock, worth $56,231. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,300Holding current value
$56,231% of portfolio
0.01%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RCKT
# of Institutions
258Shares Held
108MCall Options Held
555KPut Options Held
177K-
Rtw Investments, LP New York, NY17.7MShares$49 Million1.93% of portfolio
-
Wellington Management Group LLP Boston, MA12.6MShares$35 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$17.2 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$14.4 Million0.68% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $210M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...